trisalicylate choline

Small moleculeexperimental

Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. Choline magnesium trisalicylate is used to relieve the pain, tenderness, inflammation (swelling), and stiffness caused by arthritis and painful shoulder. It is also used to relieve pain and lower fever. Salicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration. — NCATS

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2003 (NCT00156299)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

[Mg++].C[N+](C)(C)CCO.OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O.OC3=C(C=CC=C3)C([O-])=O
Mol. weight
539.8142 g/mol
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ((1,2-ethanediylbis(carbamodithioato))(2-))manganese, mixt. with ((1,2-ethanediylbis(carbamodithioato))(2-))zinc &2(or 4)-isooctyl-4,6(or 2,6)-dinitrophenyl 2-buten oate
  • choline magnesium trisalicylate
  • choline magnesium trisalicylate
  • choline magnesium trisalicylate
  • choline magnesium trisalicylate
  • choline magnesium trisalicylate
  • tegunor
  • tricosal
  • trilisate
  • trilisate
  • trisalicylate choline

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01009931Phase 2Mar 1, 2011Biosuccess Biotech Co., Ltd., National Cancer Institute (NCI), Rutgers University
NCT02144675Phase 2Jan 1, 2009National Cancer Institute (NCI), Rutgers University
NCT00156299Phase 1Mar 1, 2003National Cancer Institute (NCI), Rutgers University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3022003
Rutgers UniversityAcademic/Hospital3322003
Biosuccess Biotech Co., Ltd.For profit1012011
3 organizations
Page 1 / 1